ASH Annual Meeting & Exposition: Leukemia

The combination of MRD-guided ibrutinib and venetoclax demonstrated feasibility for treating patients with relapsed/refractory chronic lymphocytic leukemia.

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations

Data from initial dose cohorts of a phase 1/2 trial indicated the agent was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

A phase 2 trial found that SY-1425 and azacitidine demonstrated clinical activity with acceptable tolerability in a heavily pretreated population of patients with relapsed/refractory acute myeloid leukemia with RARA positivity.

In preliminary findings from the ongoing first-in-human KOMET-001 trial, KO-539 showed activity in patients with relapsed or refractory acute myeloid leukemia.

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.

This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.

Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.

Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.

Following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Treatment with the combination regimen improved progression-free survival (PFS) and overall survival (OS) over a 5-year period compared with patients treated with bendamustine and rituximab.

Naval Daver, MD, explains the progress made on 3 abstracts he’s involved with regarding acute myeloid leukemia (AML) at the ASH Annual Meeting and Exposition.

Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial.

The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia.

The triplet regimen consisting of acalabrutinib, venetoclax, and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia

First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia.

In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.

Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.

Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.

Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia.

Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients.

Acalabrutinib continues to yield high response rates in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The novel agent ivosidenib is well tolerated and induces durable responses in patients with relapsed/refractory acute myeloid leukemia and other hematologic malignancies.

Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia.

A combination of ibrutinib plus standard chemoimmunotherapy induces deep responses in a relatively high-risk group of previously untreated, young chronic lymphocytic leukemia patients, according to a new study.

Adults with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia are very likely to achieve complete response with intensive combination induction chemotherapy, according to a retrospective review presented at the ASH Annual Meeting.